Narrative
40% of all cancer patients, who are cured of their disease, receive radiotherapy as part of their treatment. The number of cancer cures could be increased if the application of radiotherapy could be improved. Research at the University of Manchester (UoM) has: led the way in identifying, validating and exemplifying the value of predictive/prognostic biomarkers of response to radiotherapy; and demonstrated, in clinical trials, the therapeutic efficacy of combining molecularly targeted agents with radiotherapy. Further, the pharmaceutical industry has incorporated these concepts into drug development programs, accelerating clinical drug development, and thus saving them time and money.Impact date | 2014 |
---|---|
Category of impact | Health impacts |
Impact level | Benefit |
Related content
-
Research output
-
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
Research output: Contribution to journal › Article › peer-review
-
Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding
Research output: Contribution to journal › Article › peer-review
-
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361
Research output: Contribution to journal › Article › peer-review
-
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit
Research output: Contribution to journal › Article › peer-review
-
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1
Research output: Contribution to journal › Article › peer-review
-
The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts
Research output: Contribution to journal › Article › peer-review